Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Explore this paper's citation graph
Summary
It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
- Type
- article
- Published
- 1997-06-01
- Cited by
- 5,896
- References
- 37
- OpenAlex
- https://openalex.org/W1931508686
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24634621
Keywords
Medicine, Gemcitabine, Pancreatic cancer, Internal medicine, Performance status
References
- Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
- Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
- Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
- Pain and depression in patients with newly diagnosed pancreas cancer.
- Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
- Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer.
- A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5‐fluorouracil, doxorubicin, and cisplatin
- Pain management of pancreatic carcinoma: a review
- 5‐Fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas
- Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.
- Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.
- Symptoms of pancreatic cancer.
- A phase II trial of 5‐fluorouracil, leucovorin, and recombinant alpha‐2b‐interferon in advanced adenocarcinoma of the pancreas
- Treatment of cancer with weekly intravenous 5‐fluorouracil
- The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.
- The memorial pain assessment card. A valid instrument for the evaluation of cancer pain
- Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer
- A phase III comparison trial of streptozotocin, mitomycin, and 5‐fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma
- Randomized study of 5‐FU and ccnu in pancreatic cancer: Report of the veterans administration surgical adjuvant cancer chemotherapy study group
- The prevalence of pain in four cancers
Cited by
- Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
- Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer.
- Neoadjuvant and adjuvant strategies for chemoradiation.
- New drugs for the treatment of cancer, 1990-2001.
- Maligne Erkrankungen des Gastrointestinaltrakts bei alten Patienten
- Chemotherapy for resectable and advanced pancreatic cancer.
- Adjuvant chemotherapy in pancreatic cancer
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
- Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
- Acute enlargement and subsequent rupture of an abdominal aortic aneurysm in a patient receiving chemotherapy for pancreatic carcinoma.
- Virulizin(R) - A review of its antineoplastic activity.
- Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma.
- RETRACTED: Biotherapeutic approaches to pancreatic cancer
- Chemotherapy for advanced pancreatic cancer.
- Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
- Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.
- Chemoradiotherapy in the Treatment of Regional Pancreatic Carcinoma: A Phase II Study
- Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer.
- Cancer in the elderly: pancreatic cancer.
- Gastrointestinal cancer: recent developments in medical oncology.
Related papers
- Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
- Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine
- Aberrant expression of circulating microRNAs in pancreatic cancer patients and in patients with gemcitabine resistance
- Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment.
- USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
- Research advances on related molecules and genes affecting the efficacy of gemcitabine for pancreatic cancer
- Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine
- An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
- Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine.